Osteoporosis Medications Marketed in Canada (August 2024)

Please see the PharmaCare Special Authority website for complete details on PharmaCare coverage in British Columbia.

Generic name, brand name, available strengths[1]	Health Canada Osteoporosis Indications[1]	Dosage and annual cost[2]		PharmaCare coverage[3]
BISPHOSPHONATES				
alendronate FOSAMAX, generics 5, 10, 70 mg tabs **alendronate + vitamin D3** FOSAVANCE, generics 70 mg/2800, 70 mg/5600 IU tabs	▪ Postmenopausal women ▪ Men ▪ Glucocorticoid induced osteoporosis	5 mg PO once a day	$410	Non-benefit
		10 mg PO once a day	$160	Regular benefit
		70 mg PO once a week	$100	
		70 mg/5600 IU PO once a week	$140	
		70 mg/2800 IU PO once a week	$210	Non-benefit
risedronate ACTONEL, ACTONEL DR, generics 5, 35, 150 mg tabs 35 mg delayed-release (DR) tabs	▪ Postmenopausal women ▪ Men ▪ Glucocorticoid induced osteoporosis	5 mg PO once a day	$730	Regular benefit
		35 mg PO once a week	$95	
		35 mg DR PO once a week	$565	Non-benefit
		150 mg PO once a month	$530	
zoledronic acid ACLASTA, generics 5 mg/100 mL vial	▪ Postmenopausal women ▪ Men ▪ Glucocorticoid induced osteoporosis	5 mg IV infusion once a year	$385	Limited Coverage
DENOSUMAB rank ligand inhibitor				
denosumab PROLIA, JUBBONTI biosimilar 60 mg/mL single prefilled syringe	▪ Postmenopausal women ▪ Men ▪ Glucocorticoid induced osteoporosis ▪ Nonmetastatic breast cancer receiving adjuvant aromatase inhibitor therapy ▪ Nonmetastatic prostate cancer receiving androgen deprivation therapy	60 mg subcut every 6 months	$420 biosimilar $950 brand	Limited Coverage *biosimilar only*
RALOXIFENE selective estrogen receptor modulator				
raloxifene EVISTA, generics 60 mg tabs	▪ Postmenopausal women	60 mg PO once a day	$205	Limited Coverage
ROMOSOZUMAB sclerostin inhibitor				
romosozumab EVENITY 105 mg single prefilled syringe	▪ Postmenopausal women	210 mg subcut once a month maximum treatment: 12 months	$8940	Limited Coverage
TERIPARATIDE synthetic parathyroid hormone				
teriparatide FORTEO, generics OSNUVO biosimilar 250 mcg/mL multidose prefilled pen or cartridge (28 doses)	▪ Postmenopausal women ▪ Men ▪ Glucocorticoid induced osteoporosis	20 mcg subcut once a day maximum treatment: 24 months	$7960 biosimilar $7960 brand	Non-benefit

tabs tablets; **PO** by mouth; **IU** international units; **IV** intravenous; **subcut** subcutaneous; [1]Health Canada Drug Product Database; [2]cost without mark-up, professional fee or administration calculated from McKesson Canada https://www.mckesson.ca/ (accessed August 29, 2024); [3]BC PharmaCare Formulary https://pharmacareformularysearch.gov.bc.ca/

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only, and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document responsible for the result obtained from the use of information in this document. Any use of this document will imply acknowledgement of this disclaimer and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2024, Province of British Columbia. All rights reserved.

BC Provincial Academic Detailing Service
Email: PAD@gov.bc.ca
Web: www.bcpad.ca